Skip to main content
. 2021 Mar 2;35(3):680–686. doi: 10.1007/s12028-021-01203-6

Table 2.

Sustained conservative therapy versus secondary hematoma evacuation

Baseline characteristics All patients
n (%)
No secondary surgery
n (%)
Secondary surgery
n (%)
Number of patients (n, %) 48 41 7
Age (mean, SD) 69.6 (13.1) 71.2 (11.8) 60.6 (17.6)
Female sex 24 (50%) 21 (51%) 3 (43%)
Past medical history
 Hypertension 23 (48%) 20 (49%) 3 (43%)
 Diabetes mellitus 6 (13%) 5 (12%) 1 (14%)
 Hypercholesterolemia 10 (21%) 9 (22%) 1 (14%)
 Ischemic stroke 4 (8%) 4 (10%) 0 (0%)
 Transient ischemic attack (TIA) 6 (13%) 6 (15%) 0 (0%)
 Previous intracerebral hemorrhage 4 (8%) 4 (10%) 0 (0%)
 Myocardial infarction 3 (6%) 3 (7%) 0 (0%)
 Atrial fibrillation/flutter 7 (15%) 7 (17%) 0 (0%)
Medication
 Anticoagulation use 16 (33%) 16 (39%) 0 (0%)
 Antiplatelet therapy 14 (29%) 13 (32%) 1 (14%)
 Antihypertensive therapy 28 (58%) 25 (61%) 1 (43%)
 Lipid lowering therapy 12 (25%) 11 (37%) 1 (14%)
Clinical condition on admission [GCS score] (median, IQR) 14 (12–15) 14 (12–15) 14 (13–15)
Intensive care unit (ICU) 13 (27%) 7 (17%) 6 (86%)
CT characteristics
 Baseline ICH volume (median, IQR) 14.1 (10.0–22.7) 12.7 (9.2–22.0)
 Intraventricular extension 20 (42%) 17 (42%) 3 (43%)
 Hydrocephalus 15 (31%) 10 (24%) 5 (71%)
Medical management
 Prothrombin complex concentrate 13 (27%) 13 (32%) 0 (0%)
 Vitamin K 8 (17%) 8 (20%) 0 (0%)
 Platelet transfusion 3 (6%) 3 (7%) 0 (0%)
 EVD placement < 24 h 6 (13%) 5 (12%) 1 (14%)
 EVD placement > 24 h 7 (15%) 3 (8%) 4 (57%)
Outcome at discharge
 mRS (median—IQR) 4 (3–4) 4 (3–4) 4 (3–4)
 mRS 0–3 17 (35%) 15 (37%) 2 (29%)
 mRS 4–5 28 (58%) 23 (56%) 5 (71%)
 Died during hospitalization 3 (6%) 3 (7%) 0 (0%)
Outcome at 3 months (n = 46, 39, 7*)
 mRS (median—IQR) 3 (2–6) 3 (2–6) 3 (2–6)
 mRS 0–3 25 (54%) 20 (51%) 5 (71%)
 mRS 4–5 8 (17%) 8 (21%) 0 (0%)
 Death 13 (28%) 11 (28%) 2 (29%)

CT computed tomography, EVD external ventricular drainage, GCS Glasgow Coma Scale score, ICH intracerebral hemorrhage, IQR interquartile range, mRS modified Rankin Scale score, SD standard deviation

*Two lost to follow-up in the no secondary surgery group